Monoclonal Antibodies Market Size Worth USD 572.62 Billion in 2032 | Emergen Research

Advertisement

Rising adoption in personalized medicine and precision therapies, expanding regulatory approvals of monoclonal antibodies by regulatory agencies across the globe, and increasing technological advancements in biotechnology and immunology are some of the factors expected to drive Monoclonal Antibodies market revenue growth

Vancouver, Nov. 28, 2023 (GLOBE NEWSWIRE) — The global monoclonal antibodies market size was USD 204.42 billion in 2022 and is expected to register a revenue CAGR of 10.8% during the forecast period. The global monoclonal antibodies market is poised for significant growth, driven by factors such as the rising adoption of personalized medicine, expanding regulatory approvals for monoclonal antibodies, and continuous technological advancements in biotechnology and immunology. These factors, along with the increasing prevalence of cancer and infectious diseases, are contributing to a surge in demand for effective and targeted monoclonal antibody-based therapies.
The market witnessed substantial developments in 2022, with major players actively contributing to advancements in monoclonal antibody-based treatments. Notably, GlaxoSmithKline plc. (GSK) and iTeos Therapeutics announced a promising partnership for the development and commercialization of EOS-448, an anti-TIGIT monoclonal antibody, showcasing the potential for next-generation immuno-oncology therapies.

Despite the positive trajectory, challenges such as the impact of the COVID-19 pandemic on manufacturing processes, higher associated manufacturing costs, and a shortage of skilled professionals have hindered revenue growth. Recent safety concerns and FDA cautionary messages regarding specific monoclonal antibodies for COVID-19 treatment, especially in light of the omicron variant, have added complexity to the market dynamics.

Advertisement

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/2533  

Key Market Insights:

Source Insights:

  • Human monoclonal antibodies (mAb) dominated the market in 2022, with the human mAb segment holding the largest revenue share. This was attributed to the popularity of Humira (Adalimumab), a human monoclonal antibody widely used in the treatment of various conditions.
  • Extensive research and development activities, coupled with high adoption of antibody therapeutics in developed countries, are expected to drive market revenue growth. The recent FDA approval of Tezspire (tezepelumab) for severe asthma treatment is a significant milestone in this regard.

Indication Insights:

  • The cancer segment accounted for the largest revenue share in 2022, fueled by the rising number of cancer cases globally and increasing interest in monoclonal antibodies for various cancer types. Monoclonal antibodies have demonstrated higher effectiveness with minimal side effects in cancer therapy.
  • The autoimmune diseases segment is expected to experience robust revenue growth, driven by technological advancements, government initiatives, and the use of monoclonal antibodies in treating autoimmune conditions.

End-Use Insights:

  • Hospitals led the end-use segment in 2022, attributing the growth to increased hospital admissions for chronic illnesses such as autoimmune diseases and rheumatoid arthritis. Monoclonal antibodies play a crucial role in precision medicine, particularly in complex conditions like cancer and autoimmune disorders.

Regional Insights:

  • North America dominated the market, accounting for the largest revenue share in 2022. The region’s advanced medical infrastructure, aging population, high healthcare consumption, and awareness regarding monoclonal antibodies contribute to market growth.
  • Europe secured the second-largest revenue share, driven by increased adoption of therapeutic antibodies, rising chronic illnesses, and supportive government policies. Key collaborations, such as Boehringer Ingelheim International GmbH and Invetx, further contribute to market expansion.
  • Asia Pacific registered the fastest revenue growth rate, propelled by factors such as the rising consumption of processed food, government initiatives in healthcare development, and technological upgrades by key market players.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/2533

Scope of Research

Report Details Outcome
Market size in 2022 USD 204.42 Billion
CAGR (2023–2032) 10.8%
Revenue forecast to 2032 USD 572.62 Billion
Base year for estimation 2022
Historical data 2019-2021
Forecast period 2023–2032
Quantitative units Revenue in USD Billion and CAGR in % from 2023 to 2032
Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered Source, indication, production type, end-use, and region
Regional scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country scope U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Benelux, Rest of Europe, China, India, Japan, South Korea, Rest of APAC, Brazil, Rest of LATAM, Saudi Arabia, UAE, South Africa, Turkey, Rest of MEA
Key companies profiled Novartis AG; Pfizer Inc; GlaxoSmithKline plc; Amgen Inc.; Merck & Co., Inc.; Daiichi Sankyo Company, Limited; Abbott Laboratories; AstraZeneca plc; Eli Lilly And Company; Johnson & Johnson Services, Inc.; Bayer AG; Bristol Myers Squibb; F. Hoffman-La Roche Ltd.; Viatris Inc.; Biogen Inc.; Thermo Fisher Scientific, Inc.; Novo Nordisk A/S; Sanofi S.A., and Teva Pharmaceutical Industries Ltd.
Customization scope 10 hours of free customization and expert consultation

MAJOR COMPANIES and Market Share Analysis

The global monoclonal antibodies market is fairly fragmented, with many large and medium-sized players accounting for the majority of market revenue. Major players are deploying various strategies, entering mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective monoclonal antibodies solutions. Some major players included in the global monoclonal antibodies market report are:

  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Amgen Inc.
  • Merck & Co., Inc.
  • Daiichi Sankyo Company, Limited
  •  Abbott Laboratories
  • AstraZeneca Plc
  • Eli Lilly And Company
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • Bristol Myers Squibb
  • F. Hoffman-La Roche Ltd.
  • Viatris Inc.
  • Biogen Inc.
  • Thermo Fisher Scientific, Inc.
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.

Strategic Development

  • On 27 May 2021, Novartis AG, a leading pharmaceutical manufacturer, and Sub-Atomic Accomplices, a clinical-stage biopharmaceutical organization, declared the beginning of the clinical trial Eympathy, a Stage 2 and 3 study, to investigate the utilization of its original DARP in therapeutic candidate ensovibep (MP0420) for the treatment of Coronavirus.
  • On 10 January 2021, Sanofi, a global drug, and medical organization, declared the acquisition of Kymab, a clinical-stage biopharmaceutical organization to add KY1005, a human monoclonal antibody targeting key immune system regulator OX40L, to its pipeline.

Direct Order Can Be Placed Through This Link [Exclusive Copy] @ https://www.emergenresearch.com/select-license/2533

Segments Covered in Report

For the purpose of this report, Emergen Research has segmented the global monoclonal antibodies market on the basis of source, indication, production type, end-use, and region:

  • Source Outlook (Revenue, USD Billion; 2019-2032)
    • Humanized mAb
    • Human mAb
    • Murine mAb
    • Chimeric mAb
  • Indication Outlook (Revenue, USD Billion; 2019-2032)
    • Cancer
  1. Breast cancer
  2. Colorectal cancer
  3. Lung cancer
  4. Ovarian cancer
  5. Others
    • Autoimmune Diseases
    • Inflammatory Diseases
    • Infectious Diseases
    • Others
  • Production Type Outlook (Revenue, USD Billion; 2019-2032)
    • In Vivo
    • In Vitro
  • Distribution Channel Outlook (Revenue, USD Billion; 2019-2032)
    • Hospitals
    • Ambulatory centers
    • Outpatient Facilities
    • Others
  • Regional Outlook (Revenue, USD Billion; 2019-2032)
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • U.K.
      • Italy
      • Spain
      • Benelux
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Rest of APAC
    • Latin America
      • Brazil
      • Rest of LATAM
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • South Africa
      • Turkey
      • Rest of MEA

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/monoclonal-antibodies-market
Curated Reports You Shouldn’t Miss: Dive In Now!

Hybrid Operating Room Market Size, Share, Trends, By Component (Surgical Instruments, Audiovisual Display Systems and Tools, Intraoperative Diagnostic Imaging Systems, Operating Room Fixtures), By Application, By End-use, and By Region and Country Forecast to 2028

Single Use/Disposable Endoscopy Market By Product (Endoscope, Visualization Systems, Endoscopic Ultrasound, Insufflator), By Application (Bronchoscopy, Urologic Endoscopy, Arthroscopy, GI endoscopy, ENT Endoscopy, Others), By End-use (Hospitals, Healthcare Centers, Clinics), and By Region Forecast to 2028

Nanorobotics Market Size, Share, Trends, By Type (Nanomanipulator, Bio-Nanorobotics, Magnetically Guided, Bacteria-Based), By Application (Nanomedicine, Biomedical, Mechanical, Others), and By Region Forecast to 2028

AI based Clinical Trials Solution Provider Market By Therapeutic Application (Oncology, Cardiovascular Disease, and Neurological Disease), By Phase, By End-use (institutes), and By Region Forecast To 2030

Veterinary Ultrasound Market, By Type [Two-Dimensional (2D), Three-Dimensional/Four Dimensional (3D/4D), and Doppler], By Product, By Technology, By Animal Type, By Application, By End-Use, and By Region Forecast to 2030

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: https://www.emergenresearch.com/

Direct Line: +1 (604) 757-9756

E-mail: [email protected]

Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.